금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Forex Today: US Dollar firms ahead of Nonfarm Payrolls as Hormuz risk returns
The US Dollar (USD) posted gains against every major currency on Thursday, with the US Dollar Index ...
Dow Jones Futures: Market Pauses With Jobs Report Due; Cloudflare, Sezzle Lead Earnings Movers
Dow Jones futures: The market pauses, but what happens next? Don't buy these AI stocks yet. Cloudfla...
US Equity Markets End Lower After Crude Oil Prices, Government Bond Yields Rise Again
US equity indexes ended lower Thursday after crude oil prices and government bond yields rose follow...
A look at which assets are following the script, and which aren’t, on day 75 of the war
Stock Market Investors Just Got Bad News About President Trump's Economy. History Says a Domino Effect Could Follow.
Accelerating inflation has made interest rate increases more likely, and they have historically been bad news for the stock market.
SharkNinja to enter S&P MidCap 400; Flowers Foods, F&G Annuities & Life to join S&P SmallCap 600
Bel Fuse prices $399M stock offering at $266.00 for acquisitions and debt paydown
Meet the AI Stock Running Rings Around Nvidia in 2026. It Could Just Be Getting Started
While Nvidia still rules the roost, investors are moving downstream to the next generation of AI winners.
Telefónica maintains outlook despite Q1 loss tied to asset sales
Precigen anticipates funding through cash flow breakeven by end of 2026 as PAPZIMEOS launch scales
The Magnificent Seven Fell 40% While the S&P Dropped 18%: Here’s How Much Tech Concentration You Can Actually Afford
I’ve been studying portfolio concentration for years, and one stat from Schwab’s On Investing podcast keeps echoing in my head. In 2022, the Magnificent Seven fell roughly 40% while the S&P 500 droppe ...
ClearPoint forecasts $52m-$56m 2026 revenue range as IRRAflow could be cash neutral as early as 2027
Oil turns lower but still above $100 as OPEC cuts 2026 global demand forecast
Cytosorbents targets operating cash flow breakeven in 2H 2026 while planning DrugSorb-ATR de novo submission in late 2026/early 2027
Leslie’s reiterates FY2026 sales $1.1B-$1.25B and adjusted EBITDA $55M-$75M as Price Drop drives traffic